RecruitingNot Applicable

High Dimensional Analysis of Immune Cells in Pediatric Patients

South Korea294 participantsStarted 2023-04-27

Plain-language summary

The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.

Who can participate

Age range2 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium. Exclusion Criteria: * Patients who have received immunomodulators, immunosuppressants, etc. * Patients with autoimmune diseases (rheumatoid arthritis, lupus, Behcet's disease, etc.) * Patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.) * Other cases where the Principal Investigator determines that it is difficult to conduct the study.

What they're measuring

Transcriptomic profile analysis of the T lymphocytes by RNA sequencing

Timeframe: until end of surgery (usually up to 12 hours from the first dose of rocuronium)

Trial details

NCT IDNCT05820802

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-04-01

View on ClinicalTrials.gov More Drug Allergy trials